Skip to main content
Sitaramesh Emani, MD, Cardiology, Columbus, OH, Ohio State University Wexner Medical Center

SitarameshEmaniMD(He/Him)

Cardiology Columbus, OH

Heart Failure & Transplantation, Interventional Cardiology

Associate Professor, Internal Medicine, Ohio State University College of Medicine

Overview of Dr. Emani

Dr. Sitaramesh Emani is a cardiologist in Columbus, OH and is affiliated with multiple hospitals in the area, including Ohio State University Wexner Medical Center and James Cancer Hospital and Solove Research Institute. He received his medical degree from Ohio State University College of Medicine and has been in practice 11 years. He is one of 160 doctors at Ohio State University Wexner Medical Center and one of 71 doctors at James Cancer Hospital and Solove Research Institute who specialize in Cardiology. He has more than 50 publications and over 500 citings.

Education & Training

  • Ohio State University Hospital
    Ohio State University HospitalFellowship, Advanced Heart Failure and Transplant Cardiology, 2012 - 2013
  • Ohio State University Hospital
    Ohio State University HospitalFellowship, Cardiovascular Disease, 2009 - 2012
  • Washington University/B-JH/SLCH Consortium
    Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2006 - 2009
  • Ohio State University College of Medicine
    Ohio State University College of MedicineClass of 2006

Certifications & Licensure

  • OH State Medical License
    OH State Medical License 2009 - 2025
  • American Board of Internal Medicine Advanced Heart Failure and Transplant Cardiology
  • American Board of Internal Medicine Interventional Cardiology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Anticoagulation Management Following Left Ventricular Assist Device Implantation Is Similar Across All Provider Strategies  
    Brent C Lampert, Sitaramesh Emani, Ahmet Kilic, Bryan A Whitson, Interactive CardioVascular and Thoracic Surgery

Press Mentions

  • FDA Approves Camzyos for the Treatment of Obstructive Hypertrophic Cardiomyopathy
    FDA Approves Camzyos for the Treatment of Obstructive Hypertrophic CardiomyopathyMay 6th, 2022
  • Why? Women More Likely to Die After Heart Attack Than Men – Study Finds
    Why? Women More Likely to Die After Heart Attack Than Men – Study FindsMarch 19th, 2022
  • Ohio State Cardiologists First in US to Perform New Heart Failure Treatment—Patient Feels ‘100% Better’
    Ohio State Cardiologists First in US to Perform New Heart Failure Treatment—Patient Feels ‘100% Better’November 5th, 2021
  • Join now to see all

Professional Memberships

Hospital Affiliations